[Chronic myelogenous leukemia complicated by drug-induced agranulocytosis]

Rinsho Ketsueki. 2011 May;52(5):278-81.
[Article in Japanese]

Abstract

We describe a patient with chronic myelogenous leukemia (CML) who developed drug-induced agranulocytosis. A 75-year-old female was diagnosed with CML in December 2001. She had been receiving imatinib therapy for more than five years. In August 2007, she was hospitalized due to a severe neutropenia 10 days after colonoscopy. She was diagnosed as having agranulocytosis induced by colonoscopy premedication including scopolamine butylbromide and flumazenil. Severe neutropenia was resolved by G-CSF treatment without CML progression. Agranulocytosis in patients with CML is rare, but potentially lethal. Here, we report the clinical course in this patient.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Agranulocytosis / chemically induced*
  • Agranulocytosis / etiology
  • Benzamides
  • Butylscopolammonium Bromide / adverse effects*
  • Colonoscopy
  • Female
  • Flumazenil / adverse effects*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Neutropenia / drug therapy
  • Neutropenia / etiology
  • Piperazines / therapeutic use
  • Premedication / adverse effects*
  • Pyrimidines / therapeutic use
  • Treatment Outcome

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Granulocyte Colony-Stimulating Factor
  • Butylscopolammonium Bromide
  • Flumazenil
  • Imatinib Mesylate